Publication: ASSESSING THE POTENTIAL OF NANO-DELIVERY SYSTEMS CONTAINING 18β-GLYCYRRHETINIC ACID IN TARGETING INFLAMMATION
| dc.contributor.author | MOHAMAD SIDDIQ BIN MOHAMAD | |
| dc.date.accessioned | 2023-10-06T15:32:05Z | |
| dc.date.available | 2023-10-06T15:32:05Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | Lung cancer is the second most common malignancy globally and the cause of the highest number of cancer-related mortality worldwide. Non-small-cell lung cancer contribute to the most of the cases. Conventional treatment methods including radiation therapy, chemotherapy and immunotherapy do exist, however they are only partially effective due to their side effects and recurrence risk. In both in vitro and in vivo investigations, 18β-Glycyrrhetinic acid (18β- Gly), a naturally occurring substance extracted from glycyrrhizic acid/glycyrrhizin of licorice plant, has demonstrated anti-cancer potential by suppressing cancer cell growth, angiogenesis and metastasis. Although 18β-Gly possess potential therapeutic abilities, the application of free 18β-Gly into clinical practices hindered due to its poor physicochemical characteristics such as poor bioavailability and low water solubility. PLGA, a synthetic polymer is great tune-able options for nano-drug delivery system which can be used for various diseases including cancer therapy. Formulating 18β-Gly into PLGA will help to overcome challenges imposed by poor physicochemical characteristics of 18β-Gly. For this research, 18β-Gly-PLGA was tested for its anti-cancer ability in A549 cell lines found in lung cancer. This study has produced results showing 18β-Gly-PLGA has great physicochemical characteristics such as sustained in vitro drug release and good entrapment efficiency. 18β-Gly-PLGA also able to inhibit A549 cells proliferation and migration. The oncogenes such as KRT18, EGFR, BRAF and KRAS were transcriptionally down-regulated as part of the underlying mechanism of 18β-Gly-PLGA anti- cancer effects. 18β-Gly-PLGA also able to significantly down-regulate cancer proliferation and migration associated proteins such as ErbB2, Survivin, M-CSF and Mesothelin. The anti- cancer ability of 18β-Gly-PLGA compared to empty PLGA to demonstrate the true potential of 18β-Gly-PLGA as anti-cancer agent. | en_US |
| dc.identifier.uri | https://hdl.handle.net/20.500.14377/32207 | |
| dc.language.iso | en | en_US |
| dc.publisher | International Medical University | en_US |
| dc.subject | Lung Neoplasms | en_US |
| dc.subject | In Vitro Techniques | en_US |
| dc.subject | Glycyrrhetinic Acid | en_US |
| dc.subject | Cell Line | en_US |
| dc.subject | Pneumonia | en_US |
| dc.title | ASSESSING THE POTENTIAL OF NANO-DELIVERY SYSTEMS CONTAINING 18β-GLYCYRRHETINIC ACID IN TARGETING INFLAMMATION | en_US |
| dc.type | Thesis | |
| dspace.entity.type | Publication |